Frost & Sullivan Predicts Growth for the European Vaccines Market

- Technology innovation and increasing focus on new vaccine development are likely to revolutionise the vaccine industry from prophylactic to therapeutic vaccines

LONDON, Sept. 11, 2012 /PRNewswire/ -- As vaccine manufacturers increasingly tend to leverage on novel technologies, and potential late-stage vaccine candidates progress the pipeline and reach the commercialization stage, the European vaccines market is expected to witness significant growth rates. Next generation vaccines such as edible plant-based vaccines could also have a significant impact on vaccines development.

New analysis from Frost & Sullivan, Analysis of the European Vaccines Market, (www.pharma.frost.com), finds that the European vaccines market earned revenues of $6.36 billion in 2011 and estimates this to reach $12.05 billion in 2018 at a compound annual growth rate (CAGR) of 9.6% from 2011-2018.

The high levels of unmet medical needs for diseases such as AIDS, malaria and tuberculosis - which affect millions of people every year and contribute to increasing healthcare expenditure - present huge growth potential and untapped market opportunities, thereby fuelling increased R&D investments and government support for vaccine development.

"The future growth of the vaccine industry is likely to be propelled by the adult vaccines segment," notes Frost & Sullivan Senior Research Analyst Aiswariya Chidambaram. "The tremendous success rates of the recently launched influenza and HPV vaccines have attracted the attention of market participants towards the adult vaccines. The vast majority of the vaccines in pipeline are novel, innovative vaccines based on new antigens, targeting malaria, tuberculosis, dengue fever, allergies and herpes."

Anticipation of capacity demand remains a key challenge for vaccine manufacturers, particularly during pandemic outbreak of diseases.

"Speculation of vaccine production capacity considering unanticipated needs such as pandemic outbreaks, epidemics and bioterrorism is likely to have a huge impact on the growth and sustenance of vaccine manufacturers in Europe," adds Chidambaram. "Vaccine manufacturers are under the compulsion to maintain excess reserve supply owing to the tender-based vaccine procurement, lest they miss out on huge business opportunities."

Accurate estimation of capacity demand and product differentiation will therefore be critical for market participants to garner a substantial share of the market.

"The highly fragmented nature of the European market will require market participants to accurately predict manufacturing capacity and fulfil global requirements during emergency situations, thereby enabling them to stay ahead of competition and prevent being hit by excess or inadequate capacity," concludes Chidambaram.

If you are interested in more information on this study, please send an email with your contact details to Anna Zanchi, Corporate Communications, at anna.zanchi@frost.com.

Analysis of the European Vaccines Market is part of the Pharmaceutical and Biotechnology Growth Partnership Service programme, which also includes research in the following markets: European Biosimilars Market and European Pharmaceutical and Biotech Contract Manufacturing Markets. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

• The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
• The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us: Start the discussion
Join Us: Join our community
Subscribe: Newsletter on "the next big thing"
Register: Gain access to visionary innovation

Contact:
Anna Zanchi
Corporate Communications – Europe
P: 0039-02-46514819
E: anna.zanchi@frost.com
http://www.frost.com